Study finds three anti-seizure drugs equally effective for severe form of epilepsy

November 27, 2019

There are three treatment options commonly used by doctors in the emergency room to treat patients with refractory status epilepticus, severe seizures that continue even after benzodiazepine medications, which are effective in controlling seizures in more than two-thirds of patients. New findings published in the New England Journal of Medicine reveal that the three drugs, levetiracetam, fosphenytoin, and valproate, are equally safe and effective in treating patients with this condition. The study was supported by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.

"Doctors can be confident that the particular treatment they choose for their patients with status epilepticus is safe and effective and may help them avoid the need to intubate the patient as well as stays in the intensive care unit," said Robin Conwit, M.D., NINDS program director and an author of the study. "This was a truly collaborative, multidisciplinary study that involved pediatricians, emergency medicine doctors, neurologists, pharmacologists, and biostatisticians all contributing their expertise."

In the Established Status Epilepticus Treatment Trial (ESETT), led by Robert Silbergleit, M.D., professor at the University of Michigan, Ann Arbor; Jordan Elm, Ph.D., professor at Medical University of South Carolina; James Chamberlain, M.D., professor at George Washington University; and Jaideep Kapur, M.B., B.S., Ph.D., professor at the University of Virginia, more than 380 children and adults were randomized to receive levetiracetam, fosphenytoin, or valproate when they came to the emergency room experiencing a seizure. The researchers were trying to determine which of the anticonvulsant drugs was most effective in stopping seizures and improving a patient's level of responsiveness within 60 minutes of administering treatment.

The results showed that the three drugs stopped seizures and improved responsiveness in approximately half of the study participants. Specifically, these benefits were seen in 47% of subjects in the levetiracetam group, in 45% of participants in the fosphenytoin group and in 46% of subjects in the valproate group. These differences were not statistically significant.

There were no differences in serious side effects among the drugs.

"Our study suggests that clinical outcomes are driven by factors other than drugs. Differences in how doctors decide to treat status epilepticus, such as when they give more drugs or when to anesthetize patients and put them on a mechanical ventilator, may be more important than the specific treatments used to control seizures in patients," said Dr. Silbergleit.

The study was stopped early when a planned interim analysis found that the drugs were equally safe and effective.

ESETT researchers utilized a clinical trial design known as response adaptive randomization to improve the study's efficiency and maximize the chances of identifying the best treatment. The study used an algorithm to determine which drugs patients would receive based on accumulating trial data.

"Using an innovative design for this clinical trial, we were able to answer this important question in a timely and cost-effective manner," said Dr. Kapur. "In addition, this design lowered risk by reducing the chances that participants could have received what might have been determined to be the least effective treatment."

Status epilepticus is characterized by individual seizures or multiple seizures close together lasting more than five minutes, with a loss of consciousness. If not treated, it can lead to severe brain damage or death. Benzodiazepines are the first line of treatment for status epilepticus and are effective in two-thirds of patients. Refractory status epilepticus occurs in those patients in whom benzodiazepines do not stop their seizures.

Additional research is needed to prevent refractory status epilepticus and to find treatment options for the patients whose seizures do not respond to the three drugs investigated in this study.
-end-
Reference: Kapur et al. "Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus," New England Journal of Medicine, November 28, 2019.

This study was supported by the NINDS (U01NS088034, U01NS088023, U01NS056975, U01NS059041, and U01NS073476).

For more information:

https://www.ninds.nih.gov/Disorders/All-Disorders/Epilepsy-Information-Page

https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Hope-Through-Research/Epilepsies-and-Seizures-Hope-Through

NINDS is the nation's leading funder of research on the brain and nervous system. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIH/National Institute of Neurological Disorders and Stroke

Related Seizures Articles from Brightsurf:

Hallucinations in people with seizures may point to suicide risk
A study from scientists at Trinity College Dublin and Royal College of Surgeons in Ireland shows that 8% of individuals with a history of seizures report hallucinations, including experiences of hearing or seeing things that are not based in reality.

Epilepsy: Seizures not forecastable as expected
Epileptic seizures can probably not be predicted by changes in brain wave patterns that were previously assumed to be characteristic precursors.

Predicting epileptic seizures might be more difficult than previously thought
By studying the brain dynamics of 28 subjects with epilepsy, scientists demonstrated there is no evidence for a previously suspected warning sign for seizures known as 'critical slowing down,' which refers to characteristic changes in the behavior of a complex system that approaches a theoretical tipping point; when this point is exceeded, there can be impactful and devastating changes.

Gene protective against fruit fly heat-induced seizures may explain some human seizures
Researchers identified a gene in fruit flies that helps prevent the hyperexcitability of specific neurons that trigger seizures.

Rethinking seizures associated with cardiac disease
Research from Washington University in St. Louis finds that mutations of a gene implicated in long QT syndrome in humans may trigger seizures because of their direct effects on certain classes of neurons in the brain -- independent from what the genetic mutations do to heart function.

UTSA reduces seizures by removing newborn neurons
Epileptic seizures happen in one of every 10 people who have experienced a traumatic brain injury (TBI).

Reducing seizures by removing newborn neurons
Removing new neurons born after a brain injury reduces seizures in mice, according to new research in JNeurosci.

Inducing seizures to stop seizures
Surgery is the only way to stop seizures in 30 per cent of patients with focal drug-resistant epilepsy.

New research could help predict seizures before they happen
A new study has found a pattern of molecules that appear in the blood before a seizure happens.

New drug could help treat neonatal seizures
A new drug that inhibits neonatal seizures in rodent models could open up new avenues for the treatment of epilepsy in human newborns.

Read More: Seizures News and Seizures Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.